Genetically engineered endostatin-lidamycin fusion proteins effectively inhibit tumor growth and metastasis.

Endostatin (ES) inhibits endothelial cell proliferation, migration, invasion, and tube formation. It also shows antiangiogenesis and antitumor activities in several animal models. Endostatin specifically targets tumor vasculature to block tumor growth. Lidamycin (LDM), which consists of an active enediyne chromophore (AE) and a non-covalently bound apo-protein (LDP), is a member of chromoprotein family of antitumor antibiotics with extremely potent cytotoxicity to cancer cells. Therefore, we reasoned that endostatin-lidamycin (ES-LDM) fusion proteins upon energizing with enediyne chromophore may obtain the combined capability targeting tumor vasculature and tumor cell by respective ES and LDM moiety.
In this study, we designed and obtained two new endostatin-based fusion proteins, endostatin-LDP (ES-LDP) and LDP-endostatin (LDP-ES). In vitro, the antiangiogenic effect of fusion proteins was determined by the wound healing assay and tube formation assay and the cytotoxicity of their enediyne-energized analogs was evaluated by CCK-8 assay. Tissue microarray was used to analyze the binding affinity of LDP, ES or ES-LDP with specimens of human lung tissue and lung tumor. The in vivo efficacy of the fusion proteins was evaluated with human lung carcinoma PG-BE1 xenograft and the experimental metastasis model of 4T1-luc breast cancer.
ES-LDP and LDP-ES disrupted the formation of endothelial tube structures and inhibited endothelial cell migration. Evidently, ES-LDP accumulated in the tumor and suppressed tumor growth and metastasis. ES-LDP and ES show higher binding capability than LDP to lung carcinoma; in addition, ES-LDP and ES share similar binding capability. Furthermore, the enediyne-energized fusion protein ES-LDP-AE demonstrated significant efficacy against lung carcinoma xenograft in athymic mice.
The ES-based fusion protein therapy provides some fundamental information for further drug development. Targeting both tumor vasculature and tumor cells by endostatin-based fusion proteins and their enediyne-energized analogs probably provides a promising modality in cancer therapy.
AuthorsWen-guo Jiang, Xin-an Lu, Bo-yang Shang, Yan Fu, Sheng-hua Zhang, Daifu Zhou, Liang Li, Yi Li, Yongzhang Luo, Yong-su Zhen
JournalBMC cancer (BMC Cancer) Vol. 13 Pg. 479 ( 2013) ISSN: 1471-2407 [Electronic] England
PMID24128285 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Endostatins
  • LDP-endostatin N-terminal fusion protein
  • Recombinant Fusion Proteins
  • endostatin-LDP C-terminal fusion protein
  • Animals
  • Antineoplastic Agents (pharmacokinetics, pharmacology, therapeutic use)
  • Breast Neoplasms (drug therapy, pathology)
  • Cell Line, Tumor
  • Cell Movement (drug effects)
  • Endostatins (pharmacokinetics, pharmacology, therapeutic use)
  • Endothelial Cells (drug effects, physiology)
  • Female
  • Humans
  • Lung (metabolism)
  • Lung Neoplasms (drug therapy, secondary)
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Recombinant Fusion Proteins (pharmacokinetics, pharmacology, therapeutic use)
  • Tissue Array Analysis
  • Tissue Distribution
  • Tumor Burden (drug effects)
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: